For the quarter ending 2026-03-31, LIMNW has $2,790,249 in assets. $2,922,845 in debts.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash | 1,907,674 | 337,655 | 724,502 | 1,338,222 |
| Prepaid and other current assets | 870,872 | 162,919 | 478,868 | 444,086 |
| Total current assets | 2,778,546 | 500,574 | 1,203,370 | 1,782,308 |
| Due from related party, non-current | - | - | 126,275 | 126,275 |
| Property and equipment, net | 11,703 | 12,221 | 12,764 | 198 |
| Total non-current assets | 11,703 | 12,221 | 139,039 | 126,473 |
| Total assets | 2,790,249 | 512,795 | 1,342,409 | 1,908,781 |
| Accounts payable and accrued expenses | 529,778 | 582,234 | 559,171 | 431,873 |
| Accrued interest, related parties | 222,558 | 203,921 | 184,869 | 165,817 |
| Due to related parties | 194,587 | 209,586 | 178,053 | 170,553 |
| Short-term debt, related parties | 1,442,500 | 1,442,500 | 1,442,500 | 1,442,500 |
| Deferred underwriting fee payable | 500,000 | 500,000 | 500,000 | 500,000 |
| Deferred underwriting fee - common stock payable | - | - | - | 7,805,000 |
| Settlement payable | - | 7,360,000 | - | - |
| Total current liabilities | 2,889,423 | 10,298,241 | 2,864,593 | 10,515,743 |
| Warrant liability | 33,422 | 29,244 | 123,579 | 200,450 |
| Total liabilities | 2,922,845 | 10,327,485 | 2,988,172 | 10,716,193 |
| Common stock, 0.0001 par value 500,000,000 shares authorized 44,877,633 and 27,064,633 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively | 4,823 | 2,706 | 2,706 | 2,601 |
| Additional paid-in capital | 39,858,028 | 29,054,337 | 29,054,337 | 20,069,442 |
| Accumulated deficit | -39,995,447 | -38,871,733 | -30,702,806 | -28,879,455 |
| Total stockholders' deficit | -132,596 | -9,814,690 | -1,645,763 | -8,807,412 |
| Total liabilities and stockholders' deficit | 2,790,249 | 512,795 | 1,342,409 | 1,908,781 |
Liminatus Pharma, Inc. (LIMNW)
Liminatus Pharma, Inc. (LIMNW)